Vor Bio: China NMPA approves telitacicept for Sjögren’s
Vor Bio (Nasdaq: VOR)/b) and partner RemeGen announced that China’s NMPA has approved for adult patients with Sjögren’s disease (SjD), the first and only approved SjD therapy in China. The decision is based on a Phase 3 trial showing statistically significant ESSDAI and clinically meaningful ESSPRI improvements, with a favorable…